The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Tafasitamab in DLBCL

Sep 28, 2020

During the 18th International Workshop on Non-Hogkin Lymphoma (iwNHL), the Chair of the Lymphoma Hub , Gilles Salles,Memorial Sloan Kettering Cancer Center, New York, US, spoke about the use of tafasitamab in patients with diffuse large B cell lymphoma (DLBCL).

Tafasitamab in DLBCL

Tafasitamab is a CD19-directed monoclonal antibody approved by the FDAin July 2020 for use in combination with lenalidomide as a second-line treatment for patients with relapsed or refractory (R/R) DLBCL. Approval was based on results from the phase II L-MIND study. In this interview, Gilles Salles discusses these results and questions how we might sequence the L-MIND regimen compared to chimeric antigen receptor (CAR) T cell therapy given that the epitope recognised by tafasitamab overlaps with the epitope targeted by CD19-directed CAR T cells.

Your opinion matters

At this year’s virtual ESH Meeting, the Lymphoma Hub Satellite Symposium will evaluate treatment options in patients with R/R DLBCL. What do you think is the most promising emerging therapy in this setting?
4 vote s - 16 hours left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month